NASDAQ:CPRX • US14888U1016
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CATALYST PHARMACEUTICALS INC (CPRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-27 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-02-04 | Baird | Initiate | Outperform |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-09 | B of A Securities | Reiterate | Buy -> Buy |
| 2024-11-18 | Stephens & Co. | Initiate | Overweight |
| 2024-11-11 | Truist Securities | Maintains | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-08-09 | Citigroup | Maintains | Buy -> Buy |
| 2024-06-06 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-03-14 | Citigroup | Initiate | Buy |
| 2024-03-07 | B of A Securities | Initiate | Buy |
| 2024-03-01 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-21 | Oppenheimer | Initiate | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 398.204M 85.90% | 491.734M 23.49% | 588.989M 19.78% | 643.19M 9.20% | 710.8M 10.51% | 770.73M 8.43% | 860.64M 11.67% | 912.27M 6.00% | 913.25M 0.11% | 977.18M 7.00% | 957.28M -2.04% | |
| EBITDA YoY % growth | 119.693M 16.21% | 232.898M 94.58% | 295.651M 26.94% | 324.87M 9.88% | 395.03M 21.60% | 409.39M 3.64% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 86.812M -14.72% | 195.124M 124.77% | 257.778M 32.11% | 283.93M 10.15% | 330.38M 16.36% | 363.67M 10.08% | 392.55M 7.94% | 427.79M 8.98% | 482.15M 12.71% | 540.49M 12.10% | 525.09M -2.85% | |
| Operating Margin | 21.80% | 39.68% | 43.77% | 44.14% | 46.48% | 47.19% | 45.61% | 46.89% | 52.79% | 55.31% | 54.85% | |
| EPS YoY % growth | 0.81 9.46% | 1.31 61.73% | 1.69 29.01% | 1.92 13.47% | 2.20 14.57% | 2.18 -0.96% | 4.72 117.03% | 5.25 11.23% | 2.19 -58.25% | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.46 2.00% | 0.45 9.46% | 0.47 11.23% | 0.53 29.37% | 0.48 5.56% | 0.51 13.64% | 0.56 20.09% | 0.55 3.85% |
| Revenue Q2Q % growth | 150.18M 6.19% | 154.93M 5.71% | 162.1M 9.24% | 175.99M 15.32% | 162.67M 8.32% | 171.4M 10.63% | 179.65M 10.83% | 187.78M 6.70% |
| EBITDA Q2Q % growth | 73.339M 0.70% | 74.059M -13.09% | 77.25M -18.34% | 100.23M 0.51% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 67.723M 6.87% | 69.419M 4.71% | 72.655M 9.64% | 82.391M 33.22% | 71.075M 4.95% | 78.294M 12.78% | 84.673M 16.54% | 79.839M -3.10% |
All data in USD
14 analysts have analysed CPRX and the average price target is 35.02 USD. This implies a price increase of 36.16% is expected in the next year compared to the current price of 25.72.
CATALYST PHARMACEUTICALS INC (CPRX) will report earnings on 2026-05-13.
The consensus EPS estimate for the next earnings of CATALYST PHARMACEUTICALS INC (CPRX) is 0.46 USD and the consensus revenue estimate is 150.18M USD.
The expected long term growth rate for CATALYST PHARMACEUTICALS INC (CPRX) is 9.32%.